Reviewing NexImmune (NASDAQ:NEXI) & Spyre Therapeutics (NASDAQ:SYRE)

Spyre Therapeutics (NASDAQ:SYRE) and NexImmune (NASDAQ:NEXI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends.

Insider & Institutional Ownership

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 9.9% of NexImmune shares are owned by institutional investors. 6.2% of Spyre Therapeutics shares are owned by insiders. Comparatively, 19.4% of NexImmune shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Spyre Therapeutics and NexImmune’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890,000.00	1,341.21	-$338.79 million	($75.14)	-0.44
NexImmune	N/A	N/A	-$32.34 million	($30.89)	-0.11

NexImmune has lower revenue, but higher earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than NexImmune, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Spyre Therapeutics and NexImmune’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	N/A	-107.71%
NexImmune	N/A	-247.17%	-167.39%

Analyst Ratings

This is a summary of current recommendations and price targets for Spyre Therapeutics and NexImmune, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	0	0	8	0	3.00
NexImmune	0	0	0	0	N/A

Spyre Therapeutics currently has a consensus target price of $41.00, suggesting a potential upside of 24.17%. Given Spyre Therapeutics’ higher probable upside, research analysts plainly believe Spyre Therapeutics is more favorable than NexImmune.

Risk & Volatility

Spyre Therapeutics has a beta of 2.93, suggesting that its share price is 193% more volatile than the S&P 500. Comparatively, NexImmune has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500.

Summary

Spyre Therapeutics beats NexImmune on 7 of the 11 factors compared between the two stocks.

About Spyre Therapeutics

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

About NexImmune

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.